Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Alcon President & CEO: Cary Rayment plans to build Alcon's international surgical and pharmaceutical businesses in Asia after assuming the joint position Oct. 1. He will seek further expansion into Japan, the firm's second largest market behind the U.S., as well as China, Korea and India. Rayment, 57, will replace Tim Sear, 67, who has been with Alcon 34 years and saw the firm through its 2002 initial public offering. In 2001, Rayment became senior-VP, directing cross-divisional efforts for surgical, pharmaceutical and consumer groups in the U.S. In January, he took responsibility for Alcon Japan. Rayment has been with Alcon since it acquired CooperVision Surgical in 1989. Kevin Buehler, 47, a 20-year Alcon veteran and VP-operations, Latin America, Canada and the Far East, will replace Rayment...

You may also be interested in...



People In Brief

FDA creates new position: Deputy Commissioner Janet Woodcock will aid Commissioner Andrew von Eschenbach in supervising FDA's scientific and medical regulatory activities as head of the newly created Office of the Chief Medical Officer, FDA announces Jan. 19. An agency employee since 1986, Woodcock has been Director of the Center for Drug Evaluation and Research and has worked in the Center for Biologics Evaluation and Research. Most recently she was Deputy Commissioner for Operations. Woodcock has been particularly active in leading the Critical Path Initiative (1"The Gray Sheet" Jan. 9, 2006, p. 4).... And names new COO: John Dyer becomes FDA Deputy Commissioner of Operations and Chief Operating Officer, bringing nearly 30 years of government experience in upper-level management. Dyer will help strengthen management, business processes and information technology at the agency, FDA says. Additionally, he will assist other deputy commissioners and the Chief of Staff in providing management leadership and oversight of the agency. Dyer most recently served as COO for CMS. He also has worked in the Social Security Administration and the Executive Branch Office of Management and Budget (2"The Gray Sheet" July 19, 2004, p. 24)...

People In Brief

FDA creates new position: Deputy Commissioner Janet Woodcock will aid Commissioner Andrew von Eschenbach in supervising FDA's scientific and medical regulatory activities as head of the newly created Office of the Chief Medical Officer, FDA announces Jan. 19. An agency employee since 1986, Woodcock has been Director of the Center for Drug Evaluation and Research and has worked in the Center for Biologics Evaluation and Research. Most recently she was Deputy Commissioner for Operations. Woodcock has been particularly active in leading the Critical Path Initiative (1"The Gray Sheet" Jan. 9, 2006, p. 4).... And names new COO: John Dyer becomes FDA Deputy Commissioner of Operations and Chief Operating Officer, bringing nearly 30 years of government experience in upper-level management. Dyer will help strengthen management, business processes and information technology at the agency, FDA says. Additionally, he will assist other deputy commissioners and the Chief of Staff in providing management leadership and oversight of the agency. Dyer most recently served as COO for CMS. He also has worked in the Social Security Administration and the Executive Branch Office of Management and Budget (2"The Gray Sheet" July 19, 2004, p. 24)...

HHS Inspector General

The Senate confirms acting Department of Health & Human Services Office of the Inspector General head Daniel Levinson as the new inspector general June 8. Levinson will step down from his position as IG of the General Services Administration, after he is sworn in at the health agency. He has served in the acting HHS role since July 2004 (1"The Gray Sheet" July 19, 2004, p. 24)...

Related Content

UsernamePublicRestriction

Register

MT020591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel